Key facts
- This page summarizes Thomas J. Hudson's Form 4 filing for AbbVie Inc. (ABBV).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Feb 2024, 17:15.
Thomas J. Hudson - 15 Feb 2024 Form 4 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- SVP, CSO, GLOBAL RESEARCH
- Issuer ticker
- ABBV
- Reported as of
- 15 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2024, 17:15:32 UTC
- Prior SEC filing
- 02 Mar 2023
- Next SEC filing
- 01 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- T.O. Odutayo, attorney-in-fact for Thomas J. Hudson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas J. Hudson filed Form 4 for AbbVie Inc. (ABBV) on 20 Feb 2024.
Change
- Previous filing in this sequence was filed on 02 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +28,322
- Change %
- +35%
- Price
- $0.000000
- Shares after
- 109,651
- Date
- 15 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +7,552
- Change %
- +6.9%
- Price
- $0.000000
- Shares after
- 117,203
- Date
- 15 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +5,350
- Change %
- +4.6%
- Price
- $0.000000
- Shares after
- 122,553
- Date
- 15 Feb 2024
- Ownership
- Direct
- Footnotes
- F3
ABBV
transaction
Common Stock, $0.01 par value
Award
- Transaction value
- $0
- Shares
- +5,348
- Change %
- +4.4%
- Price
- $0.000000
- Shares after
- 127,901
- Date
- 15 Feb 2024
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
transaction
Derivative
Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +18,912
- Change %
- Price
- $0.000000
- Shares after
- 18,912
- Date
- 15 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,912
- Exercise price
- $0.000000
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
Footnote F2
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
Footnote F3
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
Footnote F4
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
Footnote F5
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,304 on February 15, 2025, 6,304 on February 15, 2026, and 6,304 on February 15, 2027.